A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Phase 2
Completed
- Conditions
- Alzheimer's Disease or Vascular Dementia
- Interventions
- Drug: BAC treatmentDrug: Matched vehicle
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Charsire Biotechnology Corp.
- Target Recruit Count
- 80
- Registration Number
- NCT02886494
- Locations
- ๐บ๐ธ
The Cognitive and Research Center of NJ, Springfield, New Jersey, United States
๐บ๐ธSPRI, Brooklyn, New York, United States
๐บ๐ธAdvanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States
BAC in Patient With Alzheimer's Disease or Vascular Dementia
Phase 2
Withdrawn
- Conditions
- Alzheimer's DiseaseVascular Dementia
- Interventions
- Other: BAC Matched VehicleDrug: BAC
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Charsire Biotechnology Corp.
- Registration Number
- NCT02467413
- Locations
- ๐จ๐ณ
National Cheng Kung University Hospital, Tainan, Taiwan
CSTC1 for Diabetic Foot Ulcers Phase II Study
Phase 2
Completed
- Conditions
- Diabetic Foot UlcerDiabetes MellitusWounds
- Interventions
- Drug: CSTC1 Matched vehicle
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Charsire Biotechnology Corp.
- Target Recruit Count
- 124
- Registration Number
- NCT01813305
- Locations
- ๐จ๐ณ
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
ยฉ Copyright 2025. All Rights Reserved by MedPath